Show Full Stories
XTo view all stories in expanded form, please subscribe.
Fly Intel: Pre-market Movers » 09:0103/2903/29/23
LCID, UNF, KC, LULU, MU, CONN, GLYC, SLGC, MINM
Check out this morning's…
GlycoMimetics reports Q4 EPS (19c), consensus (17c) » 07:1003/2903/29/23
As of December 31, 2022,…
As of December 31, 2022, GlycoMimetics had cash and cash equivalents of $47.9M as compared to $90.3M as of December 31, 2021. In the first quarter, GlycoMimetics raised a total of $28.7M from sales of shares of common stock under its existing ATM facility. "In 2022, we made great strides in our continued organizational evolution, strengthening our leadership team and financial position as we aspire to become a commercial-stage company capable of delivering uproleselan to R/R AML patients in need of innovative new treatment options," said Harout Semerjian, CEO of GlycoMimetics. "Patients continue to live longer in our pivotal Phase 3 study of uproleselan, with duration of median follow-up for the blinded, pooled patient population now at a remarkable 25 months. Our Phase 3 AML trial projects to have the longest duration of median follow-up at time of primary analysis of any study, to our knowledge, previously conducted in this disease area. We remain optimistic and excited about the potential of uproleselan to improve overall survival in R/R AML."
|Over a week ago|
GlycoMimetics considers SVB exposure 'immaterial' » 17:0803/1003/10/23
In a regulatory filing,…
In a regulatory filing, GlycoMimetics (GLYC) said it currently maintains an account at Silicon Valley Bank (SIVB) holding cash deposits of approximately $2M, which amount the company considers to be immaterial to its liquidity.
|Over a month ago|
GlycoMimetics price target lowered to $8 from $13 at H.C. Wainwright » 12:1402/1502/15/23
H.C. Wainwright lowered…
H.C. Wainwright lowered the firm's price target on GlycoMimetics to $8 from $13 and keeps a Buy rating on the shares. The analyst cites dilution from the capital raise and a pushing out of the launch expectation for uproleselan for the target drop.
GlycoMimetics:Uproleselan in RR study continues with original even trigger event » 08:3202/1502/15/23
GlycoMimetics announced the independent Data Monitoring Committee, DMC, reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory, R/R, acute myeloid leukemia, AML, and recommended the study should continue to the originally planned final overall survival event trigger. "We thank the independent DMC for its recommendation and are strongly encouraged as the blinded pooled survival data continues to show patients living longer than historical benchmarks. Going forward, survival duration for new events in the study will be greater than 14 months since the last patient was randomized, giving us confidence in the potential for uproleselan to improve outcomes for people living with R/R AML," said Harout Semerjian, Chief Executive Officer of GlycoMimetics. "We are proud to be advancing a novel treatment with significant potential to address the urgent unmet medical need in this acute leukemia, and we look forward to continuing the study to the originally planned final overall survival analysis, now expected within the first half of 2024."
GlycoMimetics management to meet virtually with Jefferies » 11:5101/3101/31/23
Healthcare Analyst Song…
Healthcare Analyst Song holds a virtual meeting with CEO Semerjian, CFO Hahn, CCO Johnson and CMO Rock on January 31 hosted by Jefferies.
Fly Insider: Terns Pharma, Best Buy among week's notable insider trades » 14:2201/0301/03/23
CHPT, TERN, GLYC, ATHA, AES, CLH, BBY, BGNE
Welcome to "Fly Insider,"…
|Over a quarter ago|
Biotech Alert: Searches spiking for these stocks today » 11:1111/1811/18/22
NBY, FIXX, OTIC, TENX, GLYC
These names in the…
GlycoMimetics reports Q3 EPS (16c), consensus (26c) » 07:1211/0911/09/22
As of September 30,…
As of September 30, GlycoMimetics had cash and cash equivalents of $51.6M as compared to $90.3M as of December 31, 2021. "Blinded pooled survival data in our pivotal Phase 3 study show patients living longer than what would be expected based on publicly available historical data. We approached the FDA as we felt an ethical obligation to conduct an interim analysis and have the independent DMC assess whether the prolonged survival observed is linked to treatment with uproleselan," said Harout Semerjian, CEO. "We are pleased the FDA is aligned with our position. Whether the DMC recommends that we continue the study as originally planned or immediately unblind for full analysis, we remain confident and excited in the potential of uproleselan to improve outcomes in relapsed/refractory AML."
GlycoMimetics appoints Edwin Rock, M.D. as CMO » 07:0309/0609/06/22
GlycoMimetics announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer, CMO. Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as we prepare for the readout of uproleselan's pivotal Phase 3 data in relapsed/refractory AML," said Harout Semerjian, Chief Executive Officer. "With this hire we continue to build a world-class leadership team dedicated to delivering our transformation from a research company to a commercially focused organization that improves outcomes for patients."